Presentation from ASRM October 18, 2004
Optimizing the ART Process Now and in the Future:
From Gonadotropins to Enhanced Evaluation of Embryonic Development

Video introduction transcript

Recombinant and Urinary Gonadotropins: Comparison of Efficacy, Safety and Consistency
by Scott C. Chappel, PhD

print this page
access the printable presentation transcript or curriculum vitae

Hi, I am Scott Chappel. Over the past forty years, gonadotropins have been the cornerstone of infertility treatment. Today, my presentation is going to deal with the urinary and recombinant versions of FSH to look at their efficacy, safety and consistency. In terms of efficacy, we will look at their pre-clinical performance, as well as their clinical performance, and compare them, looking at their safety in terms of the way in which they are manufactured and purified and, finally, looking at their consistency in terms of how they are batch-to-batch relative to their clinical performance.

http://www.gonadotropin.org